Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835059 | 0.85 | IDO1 (0.47) | MAPTCYP19A1IDO1 | |
| SCHEMBL29447948 | 0.85 | IDO1 (0.47) | MAPTCYP19A1IDO1 | |
| SCHEMBL21491851 | 0.73 | CA1 (0.56) | CA1CA2PSEN1PSEN2APH1B | |
| SCHEMBL8699126 | 0.73 | ALDH1A1 (0.37) | CA1CA2PSEN1PSEN2APH1B | |
| SCHEMBL6570371 | 0.72 | CYP19A1 (0.54) | MTNR1AMTNR1BCYP19A1 | |
| SCHEMBL1689627 | 0.72 | CYP19A1 (0.54) | MTNR1AMTNR1BCYP19A1 | |
| SCHEMBL15701675 | 0.72 | CYP19A1 (0.54) | MTNR1AMTNR1BCYP19A1 | |
| SCHEMBL11365140 | 0.72 | CES1 (0.48) | CA1CA2MAOAMAOBMTNR1A | |
| SCHEMBL7214509 | 0.72 | IDO1 (0.41) | CA1CA2PSEN1PSEN2APH1B | |
| SCHEMBL6978860 | 0.70 | MAOA (0.56) | CA1CA2MAOAMAOBMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552044-B2 | Dopamine receptors | H. LUNDBECK A/S (DK) | 2003-04-22 | — | — | US | disclosed |
| EP-0946542-B1 | INDANE OR DIHYDROINDOLE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2002-10-09 | — | — | EP | disclosed |
| US-6352988-B2 | HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION | H. LUNDBECK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
| US-20010021777-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-13 | — | — | US | disclosed |
| US-20010020095-A1 | Indane or dihydroindole derivatives | H. LUNDBECK A/S (DK) | 2001-09-06 | — | — | US | disclosed |
| US-6262087-B1 | HAVE HIGH AFFINITY FOR D4 RECEPTORS; USEFUL IN THE TREATMENT OF CERTAIN PSYCHIATRIC AND NEUROLOGIC DISORDERS, INCLUDING PSYCHOSIS, DEPRESSION AND ANXIETY. | H. LUNDBECK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| EP-0946542-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028293-A1 | INDANE OR DIHYDROINDOLE DERIVATIVES | H.LUNDBECK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020095-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | MAOB 657/4885CA1 2350/4885CA2 1962/4885 |
| US-20010021777-A1 | Indane or dihydroindole derivatives | HTR4, GPR4, GPR174 | MAOB 657/4885CA1 2350/4885CA2 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.